To develop a computer model to predict patients with nonalcoholic steatohepatitis (NASH) using machine learning (ML).This retrospective study utilized two databases: a) the National Institute of Diabetes and Digestive Kidney Diseases (NIDDK) fatty liver disease (NAFLD) adult database (2004-2009), b) Optum® de-identified Electronic Health Record dataset (2007-2018), real-world representative common electronic health records in United States. We developed an ML NASH, confirmed NASH non-NASH...

In 2007 the US Congress created priority review voucher program to encourage development of drugs for neglected diseases. Under program, developer a drug that treats disease receives both faster by Food and Drug Administration different drug. The can sell voucher. We estimated commercial value using sales new treatments approved in period 2007–09. A third comes from capturing market share competitors, nearly half earlier because expedited review, less than quarter lengthening time between...

Components in 4CMenB vaccine against Neisseria meningitidis serogroup B have shown to potentially cross-react with gonorrhoeae. We modeled the theoretical impact of a US vaccination program on gonorrhea outcomes. A decision-analysis model was populated using published healthcare utilization and cost data. two-dose adolescent campaign assumed, protective immunity starting at age 15 years base-case efficacy 20%. The 20%-efficacy level is an assumption since no clinical data yet quantified...

Psoriasis Area and Severity Index (PASI) response rates have been the benchmark for evaluating treatment efficacy in trials involving moderate-to-severe psoriasis.To understand how dermatologists assess biologics which trade-off rules they apply when planning psoriasis treatment.Two online surveys of 130 129 US (surveys 1 2, respectively) were conducted with use direct indirect elicitation via discrete choice experiment. Respondents asked to choose hypothetical on basis 6 attributes (a ≥75%...

Abstract The NASHmap model is a non-invasive tool using 14 variables (features) collected in standard clinical practice to classify patients as probable nonalcoholic steatohepatitis (NASH) or non-NASH, and here we have explored its performance prediction accuracy. National Institute of Diabetes Digestive Kidney Diseases (NIDDK) NAFLD Adult Database the Optum Electronic Health Record (EHR) were used for patient data. Model metrics calculated from correct incorrect classifications 281 NIDDK...

As new migraine therapies emerge, it is crucial for measures to capture the complexities of health-related quality life (HRQoL) improvement beyond improvements in monthly day (MMD) reduction. Investigations into correlations between MMD reduction, symptom management, and HRQoL are lacking, particularly those that focus on canonical symptoms patient-identified most-bothersome (PI-MBS), patients treated with eptinezumab. This exploratory analysis identified efficacy mediating effect...

Background: Ranibizumab and aflibercept are alternative anti-vascular endothelial growth factor agents approved for the treatment of visual impairment (VI) due to diabetic macular edema (DME). Objective: To estimate, from a UK healthcare perspective, cost-effectiveness ranibizumab 0.5 mg pro re nata (PRN) treat extend (T&E) compared with 2 every 8 weeks after five initial monthly doses (2q8) in VI DME. Methods: A Markov model previously reviewed by National Institute Health Care Excellence...

Patient-reported outcomes can measure domains that are personally meaningful, such as life engagement, which reflects motivation, pleasure, and well-being. This study explored whether certain items from the Inventory of Depressive Symptomatology Self-Report (IDS-SR) capture patient engagement in major depressive disorder (MDD).IDS-SR were identified by a) a panel expert psychiatrists (n = 4), b) interviews 20), c) principal component analysis (PCA) to explore clustering items. Psychometric...

The intravitreal anti-vascular endothelial growth factor treatments ranibizumab and aflibercept have proven efficacy in clinical trials, but their real world usage central retinal vein occlusion (CRVO) has not been assessed. We therefore evaluated the treatment patterns of both drugs a US claims database. IMS Integrated Data Warehouse was used to identify patients with CRVO USA for or between 24 September 2012 31 March 2014 at least 12 months follow-up. Patients were required had no...

PurposeRanibizumab, an anti-vascular endothelial growth factor, and dexamethasone, a corticosteroid, have been shown to be effective in treating macular oedema secondary retinal vein occlusion (RVO) (central RVO (CRVO) branch (BRVO)). Their real-world usage, however, has yet compared. We therefore evaluated ophthalmology visits for both drugs using US patient-level data.MethodsThe IMS Health Real-World Data Medical Claims database was used identify treatment-naive patients receiving...

Improved patient life engagement is a meaningful treatment goal in schizophrenia that cannot be satisfactorily measured using existing tools. This research aimed to determine whether certain items from the Positive and Negative Syndrome Scale (PANSS) can assess schizophrenia.

Investment by manufacturers in research and development of vaccines is relatively low compared with that pharmaceuticals. If current evaluation technologies favour drugs over vaccines, then the market becomes less attractive to manufacturers.We developed a mathematical model simulating decision-making process regulators payers, order understand manufacturers' economic incentives invest rather than curative treatments. We analysed objectives strategies payers when considering investment...

To date, real-world evidence on persistence to anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibodies (mAbs) or onabotulinumtoxinA have excluded eptinezumab. This retrospective cohort study was performed compare treatment persistency among patients with migraine anti-CGRP mAbs (erenumab, fremanezumab, galcanezumab, eptinezumab) onabotulinumtoxinA.This used IQVIA PharmMetrics data. Adult treated an mAb who had 12 months of continuous insurance enrollment before starting were...

This post hoc analysis aimed to estimate eptinezumab's therapeutic effect on health utilities and determined which extent monthly migraine days (MMDs) explain changes in utilities.DELIVER, a randomized, double-blind, placebo-controlled phase 3b trial (NCT04418765), investigated eptinezumab efficacy safety patients with 2-4 prior treatment failures. Regression explored the relationship between utility scores MMDs, as covariate along MMDs identify any MMD-independent utilities. Path quantified...